JP2002501041A5 - - Google Patents

Download PDF

Info

Publication number
JP2002501041A5
JP2002501041A5 JP2000528531A JP2000528531A JP2002501041A5 JP 2002501041 A5 JP2002501041 A5 JP 2002501041A5 JP 2000528531 A JP2000528531 A JP 2000528531A JP 2000528531 A JP2000528531 A JP 2000528531A JP 2002501041 A5 JP2002501041 A5 JP 2002501041A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
alkylene
heterocyclyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000528531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002501041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/001663 external-priority patent/WO1999037607A1/en
Publication of JP2002501041A publication Critical patent/JP2002501041A/ja
Publication of JP2002501041A5 publication Critical patent/JP2002501041A5/ja
Pending legal-status Critical Current

Links

JP2000528531A 1998-01-27 1999-01-27 カリウムチャネル阻害剤 Pending JP2002501041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7271998P 1998-01-27 1998-01-27
US60/072,719 1998-01-27
PCT/US1999/001663 WO1999037607A1 (en) 1998-01-27 1999-01-27 Potassium channel inhibitors

Publications (2)

Publication Number Publication Date
JP2002501041A JP2002501041A (ja) 2002-01-15
JP2002501041A5 true JP2002501041A5 (https=) 2006-01-26

Family

ID=22109343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000528531A Pending JP2002501041A (ja) 1998-01-27 1999-01-27 カリウムチャネル阻害剤

Country Status (21)

Country Link
US (1) US6333337B1 (https=)
EP (1) EP1051394B1 (https=)
JP (1) JP2002501041A (https=)
KR (1) KR20010034377A (https=)
CN (1) CN1294577A (https=)
AT (1) ATE265426T1 (https=)
AU (1) AU745845B2 (https=)
BR (1) BR9907236A (https=)
CA (1) CA2317457A1 (https=)
DE (1) DE69916792D1 (https=)
HU (1) HUP0101269A3 (https=)
ID (1) ID25853A (https=)
IL (1) IL137219A0 (https=)
NO (1) NO20003600L (https=)
NZ (1) NZ505666A (https=)
PL (1) PL341859A1 (https=)
RU (1) RU2218330C2 (https=)
TR (1) TR200002191T2 (https=)
TW (1) TW542823B (https=)
WO (1) WO1999037607A1 (https=)
ZA (1) ZA99550B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
AU754204B2 (en) * 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
JP2003510257A (ja) * 1999-09-22 2003-03-18 コグネティックス・インコーポレイテッド カッパ−コノトキシンpviiaの使用
AU781365B2 (en) * 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
US6566380B2 (en) * 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) * 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7470518B2 (en) 2002-02-12 2008-12-30 Cellectricon Ab Systems and method for rapidly changing the solution environment around sensors
EP1476536B1 (en) 2002-02-12 2011-07-20 Cellectricon Ab Systems and methods for rapidly changing the solution environment around sensors
US20030199578A1 (en) * 2002-04-19 2003-10-23 Turner Sean C. Naphthalene amides as potassium channel openers
BR0309940A (pt) * 2002-05-08 2005-02-09 Bayer Healthcare Ag Derivados de hidróxi-tetraidro-naftaleniluréia
WO2004052846A1 (en) * 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
DK1572632T3 (da) * 2002-12-09 2008-10-27 Xention Ltd Tetrahydro-naphthalenderivater som vanilloidreceptorantagonister
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
DE502004002403D1 (de) 2003-10-08 2007-02-01 Schering Ag Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005017316A1 (de) * 2005-04-14 2006-10-19 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1834948A1 (de) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP2010170A2 (en) * 2006-04-14 2009-01-07 Novartis AG Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
BRPI0716715B1 (pt) * 2006-08-23 2021-07-06 Xenon Pharmaceuticals, Inc Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
CA2670966A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (https=) 2011-07-01 2018-04-28
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP4074696B1 (en) 2021-10-27 2026-02-04 Shanghai Zhimeng Biopharma, Inc. N-[4-(6-fluoro-3,4-dihydro-2(1h)-isoquinolinyl)-2,6-dimethylphenyl]-1-methyl-cyclopropane-acetamide, a potassium channel regulator for the treatment of epilepsy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
US4005140A (en) 1974-02-07 1977-01-25 American Cyanamid Company Ureidotetralin compounds
US3953506A (en) 1974-02-07 1976-04-27 American Cyanamid Company Ureidotetralin compounds
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) 1987-11-18 1994-05-30 Tanabe Seiyaku Co Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them
PT89205B (pt) 1987-12-14 1993-06-30 Beecham Group Plc Processo para a preparacao de derivados de indano
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
DE69032725T2 (de) * 1989-05-31 1999-04-08 Pharmacia & Upjohn Co., Kalamazoo, Mich. ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate
US5215985A (en) 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5631275A (en) 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
FR2717805B1 (fr) 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU5772396A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU1582197A (en) 1996-01-22 1997-08-11 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6048877A (en) 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents

Similar Documents

Publication Publication Date Title
JP2002501041A5 (https=)
RU2000122451A (ru) Ингибиторы калиевого канала
RU2218330C2 (ru) Ингибиторы калиевого канала
RU2213089C2 (ru) Моноциклические бензамиды производных 3- или 4-замещенного 4-(аминометил)пиперидина, способы их получения, фармацевтическая композиция, способ ее приготовления, производное карбоновой кислоты
JP4510372B2 (ja) アシルフェニル尿素誘導体、その製造方法及び医薬としてのその使用
JP2006504766A5 (https=)
WO1998004521B1 (en) Potassium channel inhibitors
WO2019023553A1 (en) COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
NZ602622A (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
KR970701698A (ko) 프로스타글란딘 i₂작용물질로서의 나프탈렌 유도체(naphthalene derivatives as prostaglandin i₂agonists)
JP2007502806A5 (https=)
IL167168A (en) Indoline compound in crystalline form for use in oral solid medicament and such oral solid medicament for treating dysuria
EA002746B1 (ru) Стимуляторы секреции гормона роста
CA2397828A1 (en) Compounds having hypolipidemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
RU2003134629A (ru) Соединения цефема
JP2004529172A5 (https=)
RU96101800A (ru) Производные амида фенилциклогексилкарбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли, фармацевтическая композиция с антиартериосклеротической и антирестенозной активностью
FR2865732B1 (fr) Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires
RU2001126566A (ru) Производные пиразол-3-она
JP2007509052A5 (https=)
ES2170758T3 (es) Antibioticos novedosos de cefalosporina y procedimientos para la preparacion de los mismos.
NO913644L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
JP2006528964A (ja) グリオキサラーゼ阻害物質